FMP
TSX
Inactive Equity
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.
16.76 CAD
-0.6100006 (-3.64%)
Valuation Date:
Dec 31, 1969 7:00 PM
Share Price on Valuation Date
$16.76
Stock Beta
0.279738
Shares Outstanding
0